Trial
NCT03817528
ITI-007 (Lumateperone Tosylate) for Schizophrenia
Phase IITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
New York State Psychiatric Institute
Collaborators
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Intervention
ITI-007
Why stopped
ITI-007 approved by FDA
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-04